Is Wide Resection Obsolete for Desmoid Tumors in Children and Adolescents? Evaluation of Histological Margins, Immunohistochemical Markers, and Review of Literature

REFERENCES

• Fletcher CDM, Bridge JA, Hogendoorn PCW, MErtens F. World Health Organization Classification of Tumours of Soft Tissue and Bone. 4th ed. Lyon: IARC Press; 2013:72–73.
   Google Scholar
• Pignatti G, Barbanti-Brodano G, Ferrari D, et al. Extraabdominal desmoid tumour. A study of 83 cases. Clin Orthop Relat Res. 2000;375:207–213.
   Google Scholar
• Reitamo JJ, Scheinin TM, Hayry P. The desmoid syndrome. New aspects in the cause, pathogenesis and treatment of the desmoid tumour. Am J Surg. 1986;151:230–237.
   PubMed Web of Science ®Google Scholar
• Weiss SW, Goldblum JR. Fibromatoses. In: Weiss SW, Goldblum JR, eds. Enzinger and Weiss's soft tissue tumours. 4th ed. St. Louis Baltimore Berlin: Mosby; 2001:309–346.
   Google Scholar
• Bertario L, Russo A, Sala P, et al. Genotype and phenotype factors as determinants of desmoid tumours in patients with familial adenomatous polyposis. Int J Cancer. 2001;95(2):102–107.
   Google Scholar
• Eccles DM, van der Luijt R, Breukel C, et al. Hereditary desmoid disease due to a frameshift mutation at codon 1924 of the APC gene. Am J Hum Genet. 1996;59(6):1193–1201.
   Google Scholar
• Scott RJ, Froggatt NJ, Trembath RC, et al. Familial infiltrative fibromatosis (desmoid tumours) (MIM135290) caused by a recurrent 3’ APC gene mutation. Hum Mol Genet. 1996;5(12):1921–1924.
   Google Scholar
• Lips DJ, Barker N, Clevers H, Hennipman A. The role of APC and beta-catenin in the etiology of aggressive fibromatosis (desmoid tumours). Eur J Surg Oncol. 2009;35(1):3–10.
   Google Scholar
• Buitendijk S, van de Ven CP, Dumans TG, et al. Pediatric aggressive fibromatosis: a retrospective analysis of 13 patients and review of literature. Cancer. 2005;104(5):1090–1099.
   Google Scholar
• Leithner A, Gapp M, Leithner K, et al. Margins in extra-abdominal desmoid tumours: a comparative analysis. J Surg Oncol. 2004;86(3):152–156.
   Google Scholar
• Soto-Miranda MA, Sandoval JA, Rao B, et al. Surgical treatment of pediatric desmoid tumours. A 12-year, single-center experience. Ann Surg Oncol. 2013;20:3384–3390.
   Google Scholar
• Meazza C, Alaggio R, Ferrari A. Aggressive fibromatosis in children: a changing approach. Minerva Pediatr. 2011;63:305–318.
   PubMed Web of Science ®Google Scholar
• Oudot C, Defachelles AS, Minard-Colin V, et al. Desmoid tumours in children: current strategy. Bull Cancer. 2013;100:518–528.
   Google Scholar
• Honeyman JN, Theilen TM, Knowles MA, et al. Desmoid fibromatosis in children and adolescents: a conservative approach to management. J Pediatr Surg. 2013;48:62–66.
   Google Scholar
• Janinis J, Patriki M, Vini L, et al. The pharmacological treatment of aggressive fibromatoses: a systematic review. Ann Oncol. 2003;14:181–190.
   PubMed Web of Science ®Google Scholar
• Ballo MT, Zagars Gk, Pollack A. Radiation therapy in the management of desmoid tumours. Int J Radiat Oncol Biol Phys. 1998;42(5):1007–1014.
   Google Scholar
• Goy BW, Lee SP, Eilber F, et al. The role of adjuvant radiotherapy in the treatment of resectable desmoid tumours. Int J Radiat Oncol Biol Phys. 1997;39(3):659–665.
   Google Scholar
• Dormans JP, Spiegel D, Meyer J, et al. Fibromatoses in childhood: the desmoid/fibromatosis complex. Med Pediatr Oncol. 2001;37(2):126–131.
   Google Scholar
• Leithner A, Gapp M, Radl R, et al. Immunohistochemical analysis of desmoid tumours. J Clin Pathol. 2005;58:1152–1156.
   PubMed Web of Science ®Google Scholar
• Liegl B, Leithner A, Bauernhofer T, et al. Immunohistochemical and mutational analysis of PDGF and PDGFR in desmoid tumours: is there a role for tyrosine kinase inhibitors in c-kit-negative desmoid tumours? Histopathology. 2006;49:576–581.
   PubMed Web of Science ®Google Scholar
• H, Urban C, Benesch M, Raith J, et al. Multimodal treatment of children with unresectable or recurrent desmoid tumours: an 11-year longitudinal observational study. J Pediatr Hematol Oncol. 2004;26:518–522.
   Google Scholar
• Lackner H, Urban C, Kerbl R, et al. Noncytotoxic drug therapy in children with unresectable desmoid tumours. Cancer. 1997;80:334–340.
   Google Scholar
• Leithner A, Schnack B, Katterschafka T, et al. Treatment of extra-abdominal desmoid tumours with interferon-alpha with of without tretinoin. J Surg Oncol. 2000;73:21–25.
   PubMed Web of Science ®Google Scholar
• Poon R, Smits R, Li C, et al. Cyclooxygenase-two (COX-2) modulates proliferation in aggressive fibromatosis (desmoid tumour). Oncogene. 2001;20:451–460.
   PubMed Web of Science ®Google Scholar
• Sorensen A, Keller J, Nielsen OS, Jensen OM. Treatment of aggressive fibromatosis: a retrospective study of 72 patients followed for 1–27 years. Acta Orthop Scand. 2002;73:213–219.
   PubMed Web of Science ®Google Scholar
• Deyrup AT, Tretiakova M, Montag AG. Estrogen receptor-beta expression in extraabdominal fibromatoses: an analysis of 40 cases. Cancer. 2006;106:208–213.
   PubMed Web of Science ®Google Scholar
• Balducci C, Lilli C, Stabellini G, et al. Human desmoid fibroblasts: matrix metalloproteinases, their inhibitors and modulation by Toremifene. BMC Cancer. 2005;5:22.
   Google Scholar
• Acker JC, Bossen EH, Halperin EC. The management of desmoid tumours. Int J Radiat Oncol Biol Phys. 1993;26:851–858.
   PubMedGoogle Scholar
• Fernberg JO, Brosjo O, Larsson O, et al. Interferon-induced remission in aggressive fibromatosis of the lower extremity. Acta Oncol. 1999;38:971–972.
   PubMed Web of Science ®Google Scholar
• Geurs F, KOk TC. Regression of a great abdominal desmoid tumour by interferon alpha. J Clin Gastroenterol. 1993;16:264–265.
   PubMedGoogle Scholar
• Skapek SX, Ferguson WS, Granowetter L, et al. Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial. J Clin Oncol. 2007;25:501–506.
   PubMed Web of Science ®Google Scholar
• Wehl G, Rossler J, Otten JE, et al. Response of progressive fibromatosis to therapy with liposomal doxorubicin. Onkologie. 2004;27:552–556.
   PubMed Web of Science ®Google Scholar
• Heinrich MC, McArthur GA, Demetri GD, et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumour). J Clin Oncol. 2006;24:1195–1203.
   PubMed Web of Science ®Google Scholar
• Signoroni S, Frattini M, Negri T, et al. Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis. Clin Cancer Res. 2007;13:5034–5040.
   PubMed Web of Science ®Google Scholar
• Mace J, Sybil Biermann J, Sondak V, et al. Response of extraabdominal desmoid tumours to therapy with imatinib mesylate. Cancer. 2002;95:2373–2379.
   PubMed Web of Science ®Google Scholar
• Alman BA, Goldberg MJ, Naber SP, et al. Aggressive fibromatosis. J Pediatr Orthop. 1992;12:1–10.
   PubMed Web of Science ®Google Scholar
• Hayry P, Reitamo JJ, Vihko R, et al. The desmoid tumour. III. A biochemical and genetic analyses. Am J Clin Pathol. 1982;77:681–685.
   PubMed Web of Science ®Google Scholar
• Lim CL, Walder MJ, Mehta RR, Das Gupta TK. Estrogen and antiestrogen binding sites in desmoid tumours. Eur J Cancer Clin Oncol. 1986;22:583–587.
   PubMedGoogle Scholar
• Maddalozzo J, Tenta LT, Hutchinson LR, et al. Juvenile fibromatosis: hormonal receptors. Int J Pediatr Otorhinolaryngol. 1993;25:191–199.
   PubMed Web of Science ®Google Scholar
• McDougall A, McGarrity G. Extra-abdominal desmoid tumours. J Bone Joint Surg Br. 1979;61-B:373–377.
   PubMed Web of Science ®Google Scholar
• Reis-Filho JS, Milanezi F, Pope LZ, et al. Primary fibromatosis of the breast in a patient with multiple desmoid tumours—report of a case with evaluation of estrogen and progesterone receptors. Pathol Res Pract. 2001;197:775–779.
   Web of Science ®Google Scholar
• Serpell JW, Tang HS, Donnovan M. Factors predicting local recurrence of desmoid tumours including proliferating cell nuclear antigen. Aust N Z J Surg. 1999;69:782–789.
   PubMedGoogle Scholar
• Ishizuka M, Hatori M, Dohi O, et al. Expression profiles of sex steroid receptors in desmoid tumours. Tohoku J Exp Med. 2006;210:189–198.
   PubMed Web of Science ®Google Scholar
• Biermann JS. Desmoid tumours. Curr Treat Options Oncol 2000;1:262–266.
   PubMedGoogle Scholar
• Chaudhuri PK, Walker MJ, Beattie CW, Das Gupta TK. Presence of steroid receptors in human soft tissue sarcomas of diverse histological origin. Cancer Res. 1980;40:861–865.
   PubMed Web of Science ®Google Scholar
• De Pas T, Bodei L, Pelosi G, et al. Peptide receptor radiotherapy: a new option for the management of aggressive fibromatosis on behalf of the Italian Sarcoma Group. Br J Cancer. 2003;88:645–647.
   PubMedGoogle Scholar
• Hoos A, Lewis JJ, Antonescu CR, et al. Characterization of molecular abnormalitites in human fibroblastic neoplasms: a model for genotype-phenotype association in soft tissue tumours. Cancer Res. 2001;61:3171–3175.
   Google Scholar
• Kouho H, Aoki T, Hisaoka M, Hashimoto H. Clinicopathological and interphase cytogenetic analysis of desmoid tumours. Histopathology. 1997;31:336–341.
   Google Scholar
• Brueckl WM, Preuss JM, Wein A, et al. Ki-67 expression and residual tumour (R) classification are associated with disease-free survival in desmoid tumour patients. Anticancer Res. 2001;21:3615–3620.
   Google Scholar
• Heidemann J, Ogawa H, Otterson MF, et al. Antiangiogenic treatment of mesenteric desmoid tumours with toremifene and interferon alfa-2b: report of two cases. Dis Colon Rectum. 2004;47: 118–122.
   Google Scholar
• Stalinska L, Turant M, Tosik D, et al. Analysis of pRb, p16INK4A proteins and proliferating antigens: PCNA, Ki-67 and MCM5 expression in aggressive fibromatosis (desmoid tumour). Histol Histopathol 2009;24:299–308.
   Google Scholar
• Yantiss RK, Spiro IJ, Compton CC, Rosenberg AE. Gastrointestinal stromal tumour versus intra-abdominal fibromatosis of the bowel wall: a clinically important differential diagnosis. Am J Surg Pathol. 2000;24:947–957.
   PubMed Web of Science ®Google Scholar
• Lucas DR, al-Abbadi M, Tabaczka P, et al. c-Kit expression in desmoid fibromatosis. Comparative immunohistochemical evaluation of two commercial antibodies. Am J Clin Pathol. 2003;119:339–345.
   Google Scholar
• Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol. 2000;13:1134–1142.
   PubMed Web of Science ®Google Scholar
• Yamaguchi U, Hasegawa T, Masuda T, et al. Differential diagnosis of gastrointestinal stromal tumour and other spindle cell tumours in the gastrointestinal tract based on immunohistochemical analysis. Virchows Arch. 2004;445:142–150.
   Google Scholar
• Miettinen M. Are desmoid tumours kit positive? Am J Surg Pathol. 2001;25:549–550.
   PubMed Web of Science ®Google Scholar
• Hornick JL, Fletcher CD. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol. 2002;117:188–193.
   PubMed Web of Science ®Google Scholar
• Gibson S, Sebire NJ, Anderson J. Platelet-derived growth factor receptors and ligands are up-regulated in paediatric fibromatosis (desmoid-tumour). Histopathology. 2007;51(6):752–757.
   Google Scholar
• Ferenc T, Wronski JW, Kopczynski J, et al. Analysis of APC, alpha-, beta-catenins, and N-cadherin protein expression in aggressive fibromatosis (desmoid tumour). Pathol Res Pract. 2009;205(5): 311–324.
   Google Scholar
• Gebert C, Hardes J, Kersting C, et al. Expression of beta-catenin and p53 are prognostic factors in deep aggressive fibromatosis. Histopathology 2007;50:491–497.
   Google Scholar
• Thway K, Gibson S, Ramsay A, Sebire NJ. Beta-Catenin Expression in Pediatric Fibroblastic and Myofibroblastic Lesions: A Study of 100 Cases. Pediatr Dev Pathol. 2009;12(4):292–296.
   Google Scholar